Published in Cancer Weekly, December 27th, 1999
"RIT with I-131 anti-B1 antibody is a promising treatment for non-Hodgkin's lymphoma (NHL)," wrote S.G. Rommelfanger and colleagues from Ann Arbor, Michigan, and Coulter Pharmaceuticals, California. "Typically treatment planning requires a tracer study with approximately six minute acquisitions of whole-body gamma camera counts (using high-energy collimation and 30 cm/min camera sweep speeds) of a patient infused with 185 MBq of radioactivity."
To facilitate the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.